Discordant growth hormone and IGF-1 levels post pituitary surgery in patients with acromegaly naïve to medical therapy and radiation: What to follow, GH or IGF-1 values?

Pituitary

Volumn 15, Issue 4, 2012, Pages 562-570

  Brzana, Jessica A ^a,b   Yedinak, Chris G ^a,b   Delashaw, Johnny B ^a,b   Gultelkin, Hume S ^a   Cook, David ^a   Fleseriu, Maria ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Acromegaly; Discordant IGF 1 GH; GH nadir; GH profile; GH suppression to glucose

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT; GLUCOSE; GROWTH HORMONE; GROWTH HORMONE RECEPTOR ANTAGONIST; HORMONE RECEPTOR BLOCKING AGENT; LIGAND; PROLACTIN; SOMATOMEDIN C; SOMATOSTATIN RECEPTOR LIGAND; UNCLASSIFIED DRUG;

ACROMEGALY; ADULT; ARTICLE; BODY MASS; CANCER RADIOTHERAPY; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; GROWTH HORMONE SECRETING ADENOMA; HISTOPATHOLOGY; HORMONE DETERMINATION; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; ORAL GLUCOSE TOLERANCE TEST; POPULATION RESEARCH; POSTOPERATIVE PERIOD; PREVALENCE; PRIORITY JOURNAL; PROTEIN DETERMINATION; RETROSPECTIVE STUDY; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY;

ACROMEGALY; ADULT; GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MIDDLE AGED; PITUITARY GLAND; RETROSPECTIVE STUDIES;

EID: 84870320908     PISSN: 1386341X     EISSN: 15737403     Source Type: Journal    
DOI: 10.1007/s11102-011-0369-1     Document Type: Article

References (33)

1. Holdaway IM, Rajasoorya C (1999) Epidemiology of acromegaly. Pituitary 2(1): 29-41
2. Fernandez A, Karavitaki N, Wass JA (2010) Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol (Oxf) 72(3): 377-382
3. Rosario PW, Calsolari MR (2011) Screening for acromegaly by application of a simple questionnaire evaluating the enlargement of extremities in adult patients seen at primary health care units. Pituitary. doi: 10.1007/s11102-011- 0302-7
4. Schneider HJ, Sievers C, Saller B, Wittchen HU, Stalla GK (2008) High prevalence of biochemical acromegaly in primary care patients with elevated IGF-1 levels. Clin Endocrinol (Oxf) 69(3): 432-435
5. Daly AF, Rixhon M, Adam C, Dempegioti A, Tichomirowa MA, Beckers A (2006) High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J Clin Endocrinol Metab 91(12): 4769-4775
6. Giustina A, Chanson P, Bronstein MD, Klibanski A, Lamberts S, Casanueva FF, Trainer P, Ghigo E, Ho K, Melmed S (2010) A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab 95(7): 3141-3148
7. Melmed S (2006) Medical progress: acromegaly. N Engl J Med 355(24): 2558-2573
8. Melmed S (2009) Acromegaly pathogenesis and treatment. J Clin Invest 119(11): 3189-3202
9. Sughrue ME, Chang EF, Gabriel RA, Aghi MK, Blevins LS (2011) Excess mortality for patients with residual disease following resection of pituitary adenomas. Pituitary 14(3): 276-283
10. Holdaway IM, Rajasoorya RC, Gamble GD (2004) Factors influencing mortality in acromegaly. J Clin Endocrinol Metab 89(2): 667-674
11. Sherlock M, Reulen RC, Alonso AA, Ayuk J, Clayton RN, Sheppard MC, Hawkins MM, Bates AS, Stewart PM(2009) ACTH deficiency, higher doses of hydrocortisone replacement, and radiotherapy are independent predictors of mortality in patients with acromegaly. J Clin Endocrinol Metab 94(11): 4216-4223
12. Fleseriu M, Delashaw JB Jr, Cook DM (2010) Acromegaly: a review of current medical therapy and new drugs on the horizon. Neurosurg Focus 29(4):E15
13. Cook DM, Ezzat S, Katznelson L, Kleinberg DL, Laws ER Jr, Nippoldt TB, Swearingen B, Vance ML (2004) AACE medical guidelines for clinical practice for the diagnosis and treatment of acromegaly. Endocr Pract 10(3): 213-225
14. Alexopoulou O, Bex M, Abs R, T'Sjoen G, Velkeniers B, Maiter D (2008) Divergence between growth hormone and insulin-like growth factor-I concentrations in the follow-up of acromegaly. J Clin Endocrinol Metab 93(4): 1324-1330
15. Elias PC, Lugao HB, Pereira MC, Machado HR, Castro M, Moreira AC (2010) Discordant nadir GH after oral glucose and IGF-I levels on treated acromegaly: refining the biochemical markers of mild disease activity. Horm Metab Res 42(1): 50-55
16. Machado EO, Taboada GF, Neto LV, van Haute FR, Correa LL, Balarini GA, Shrank Y, Goulart M, Gadelha MR (2008) Prevalence of discordant GH and IGF-I levels in acromegalics at diagnosis, after surgical treatment and during treatment with octreotide LAR. Growth Horm IGF Res 18(5): 389-393
17. Freda PU, Wardlaw SL, Post KD (1998) Long-term endocrinological follow-up evaluation in 115 patients who underwent transsphenoidal surgery for acromegaly. J Neurosurg 89(3): 353-358
18. Jane JA Jr, Starke RM, Elzoghby MA, Reames DL, Payne SC, Thorner MO, Marshall JC, Laws ER Jr, Vance ML (2011) Endoscopic transsphenoidal surgery for acromegaly: remission using modern criteria, complications, and predictors of outcome. J Clin Endocrinol Metab 96(9): 2732-2740
19. Wu TE, Lin HD, Lu RA, Wang ML, Chen RL, Chen HS (2010) The role of insulin-like growth factor-1 and growth hormone in the mortality of patients with acromegaly after trans-sphenoidal surgery. Growth Horm IGF Res 20(6): 411-415
20. Kauppinen-Mäkelin R, Sane T, Reunanen A, Välimäki MJ, Niskanen L, Markkanen H, Löyttyniemi E, Ebeling T, Jaatinen P, Laine H, Nuutila P, Salmela P, Salmi J, Stenman U-H, Viikari J, Voutilainen E (2005) A nationwide survey of mortality in acromegaly. J Clin Endocrinol Metab 90(7): 4081-4086
21. Karavitaki N, Fernandez A, Fazal-Sanderson V, Wass JA (2009) The value of the oral glucose tolerance test, random serum growth hormone and mean growth hormone levels in assessing the postoperative outcome of patients with acromegaly. Clin Endocrinol (Oxf) 71(6): 840-845
22. Sherlock M, Aragon Alonso A, Reulen RC, Ayuk J, Clayton RN, Holder G, Sheppard MC, Bates A, Stewart PM (2009) Monitoring disease activity using GH and IGF-I in the follow-up of 501 patients with acromegaly. Clin Endocrinol (Oxf) 71(1): 74-81
23. Clemmons DR (2011) Clinical laboratory indices in the treatment of acromegaly. Clin Chim Acta; Int J Clin Chem 412(5-6): 403-409
24. Carmichael JD, Bonert VS, Mirocha JM, Melmed S (2009) The utility of oral glucose tolerance testing for diagnosis and assessment of treatment outcomes in 166 patients with acromegaly. J Clin Endocrinol Metab 94(2): 523-527
25. Kamenicky P, Dos Santos C, Espinosa C, Salenave S, Galland F, Le Bouc Y, Maison P, Bougnères P, Chanson P (2009) D3 GH receptor polymorphism is not associated with IGF1 levels in untreated acromegaly. Euro J Endocrinol 161(2): 231-235
26. Vierhapper H, Heinze G, Gessl A, Exner M, Bieglmayr C (2003) Use of the oral glucose tolerance test to define remission in acromegaly. Metabolism 52(2): 181-185
27. Boero L, Manavela M, Danilowicz K, Alfieri A, Ballarino MC, Chervin A, Garcia-Basavilbaso N, Glerean M, Guitelman M, Loto MG, Nahmias JA, Rogozinski AS, Servidio M, Vitale NM, Katz D, Fainstein Day P, Stalldecker G, Mallea-Gil MS (2011) Comparison of two immunoassays in the determination of IGF-I levels and its correlation with oral glucose tolerance test (OGTT) and with clinical symptoms in acromegalic patients. Pituitary. doi: 10.1007/s11102-011-0351-y
28. Faje AT, Barkan AL (2010) Basal, but not pulsatile, growth hormone secretion determines the ambient circulating levels of insulin-like growth factor-I. J Clin Endocrinol Metab 95(5): 2486-2491
29. Freda PU (2009) Monitoring of acromegaly: what should be performed when GH and IGF-1 levels are discrepant? Clin Endocrinol (Oxf) 71(2): 166-170
30. Minuto FM, Resmini E, Boschetti M, Rebora A, Fazzuoli L, Arvigo M, Giusti M, Ferone D (2011) Biochemical diagnosis and assessment of disease activity in acromegaly: a two-decade experience. Pituitary. doi: 10.1007/s11102-011-0313-4
31. Milani D, Carmichael JD, Welkowitz J, Ferris S, Reitz RE, Danoff A, Kleinberg DL (2004) Variability and reliability of single serum IGF-I measurements: impact on determining predictability of risk ratios in disease development. J Clin Endocrinol Metab 89(5): 2271-2274
32. Clemmons DR (2011) Consensus statement on the standardization and evaluation of growth hormone and insulin-like growth factor assays. Clin Chem 57(4): 555-559
33. Arafat AM, Mohlig M, Weickert MO, Perschel FH, Purschwitz J, Spranger J, Strasburger CJ, Schofl C, Pfeiffer AF (2008) Growth hormone response during oral glucose tolerance test: the impact of assay method on the estimation of reference values in patients with acromegaly and in healthy controls, and the role of gender, age, and body mass index. J Clin Endocrinol Metab 93(4): 1254-1262